Literature DB >> 7774053

Response of scid mice to establishment of Leishmania major infection.

R A Guy1, M Belosevic.   

Abstract

The initiation of Leishmania major infection in susceptible BALB/c mice is regulated by interferon-gamma (IFN-gamma). To examine further the mechanisms of IFN-gamma-dependent regulation of the establishment of L. major, we studied the characteristics of the infection in severe combined immunodeficient (scid) mice. In the first 2 weeks of infection, we observed a delay in the development of the lesions in the footpads and lower numbers of parasites in scid compared with BALB/c mice. By week 5 after infection, the size of the leishmanial lesion was similar in both strains of mice, but the number of parasites in scid mice was 100-fold higher than in BALB/c. Treatment with anti-IFN-gamma during the establishment of L. major did not alter the course of infection in scid mice, while it exacerbated lesion development in BALB/c mice. Macrophages from scid mice were unable to kill L. major when stimulated with IFN-gamma in vitro, and produced lower levels of nitric oxide compared with macrophages from susceptible BALB/c or the resistant C57Bl/6 mice. We examined whether delayed lesion development in scid mice was due to their inability to mount appropriate inflammatory responses. While significantly fewer nucleated cells were present in the footpads of scid mice compared with BALB/c, 2 and 3 weeks after infection, no difference in inflammatory response between scid and BALB/c mice was observed in response to L. major antigen in the footpads. In contrast, there was a dramatic increase in the number of cells in the popliteal lymph nodes of BALB/c mice. Decreased inflammatory responses of scid mice in the footpad (at the site of infection) may contribute to slower development of leishmanial lesions during the first 2 weeks of infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7774053      PMCID: PMC1534477          DOI: 10.1111/j.1365-2249.1995.tb03719.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

Review 1.  Lymphokine-activated killer cells, natural killer cells and cytokines.

Authors:  B Perussia
Journal:  Curr Opin Immunol       Date:  1991-02       Impact factor: 7.486

2.  Fluorogenic substrate detection of viable intracellular and extracellular pathogenic protozoa.

Authors:  P R Jackson; M G Pappas; B D Hansen
Journal:  Science       Date:  1985-01-25       Impact factor: 47.728

3.  Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice.

Authors:  T M Scharton; P Scott
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

4.  Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production.

Authors:  K Handa; R Suzuki; H Matsui; Y Shimizu; K Kumagai
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

5.  A severe combined immunodeficiency mutation in the mouse.

Authors:  G C Bosma; R P Custer; M J Bosma
Journal:  Nature       Date:  1983-02-10       Impact factor: 49.962

6.  Murine cutaneous leishmaniasis: resistance in reconstituted nude mice and several F1 hybrids infected with Leishmania tropica major.

Authors:  G F Mitchell
Journal:  J Immunogenet       Date:  1983-10

7.  A limiting dilution assay for quantifying Leishmania major in tissues of infected mice.

Authors:  R G Titus; M Marchand; T Boon; J A Louis
Journal:  Parasite Immunol       Date:  1985-09       Impact factor: 2.280

8.  Metacyclogenesis is a major determinant of Leishmania promastigote virulence and attenuation.

Authors:  R da Silva; D L Sacks
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

9.  Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid).

Authors:  K Dorshkind; S B Pollack; M J Bosma; R A Phillips
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

10.  Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major.

Authors:  S Stenger; H Thüring; M Röllinghoff; C Bogdan
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  6 in total

1.  CD4(+) cells are indispensable for ulcer development in murine cutaneous leishmaniasis.

Authors:  M Terabe; T Kuramochi; M Ito; T Hatabu; C Sanjoba; K P Chang; T Onodera; Y Matsumoto
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

2.  Inbred strains derived from feral mice reveal new pathogenic mechanisms of experimental leishmaniasis due to Leishmania major.

Authors:  Besma E C Babay; Hechmi Louzir; Chahnaz Kebaïer; Samir Boubaker; Koussay Dellagi; Pierre-André Cazenave
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

3.  Deletion of IL-4 receptor alpha on dendritic cells renders BALB/c mice hypersusceptible to Leishmania major infection.

Authors:  Ramona Hurdayal; Natalie E Nieuwenhuizen; Mélanie Revaz-Breton; Liezel Smith; Jennifer C Hoving; Suraj P Parihar; Boris Reizis; Frank Brombacher
Journal:  PLoS Pathog       Date:  2013-10-24       Impact factor: 6.823

4.  Lymphocytes influence Leishmania major pathogenesis in a strain-dependent manner.

Authors:  Md Abu Musa; Risa Nakamura; Asma Hena; Sanjay Varikuti; Hira L Nakhasi; Yasuyuki Goto; Abhay R Satoskar; Shinjiro Hamano
Journal:  PLoS Negl Trop Dis       Date:  2019-11-18

5.  Cinnamic Acid Bornyl Ester Derivatives from Valeriana wallichii Exhibit Antileishmanial In Vivo Activity in Leishmania major-Infected BALB/c Mice.

Authors:  Anita Masic; Ana Maria Valencia Hernandez; Sudipta Hazra; Jan Glaser; Ulrike Holzgrabe; Banasri Hazra; Uta Schurigt
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

6.  2,3,7,8-tetrachlorodibenzo-p-dioxin slows the progression of experimental cutaneous Leishmaniasis in susceptible BALB/c and SCID mice.

Authors:  Gregory K DeKrey; Riane E Teagarden; Jerica L Lenberg; Richard G Titus
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.